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Introduction {#acn3788-sec-0001}
============

Alzheimer\'s disease (AD) amyloid‐*β* and *tau* deposits are accompanied by microglial activation and other signs of innate immune activation (inflammation). Early clinical observations,[1](#acn3788-bib-0001){ref-type="ref"} and subsequent pharmaco‐epidemiological data,[2](#acn3788-bib-0002){ref-type="ref"} suggested that nonsteroidal anti‐inflammatory drugs (NSAIDs) prevent subsequent development of AD symptoms. Clinical trials failed to confirm this effect, however,[3](#acn3788-bib-0003){ref-type="ref"}, [4](#acn3788-bib-0004){ref-type="ref"}, [5](#acn3788-bib-0005){ref-type="ref"} and we know of no human studies regarding NSAID effects on CNS immune activity. Among participants in a recently completed 2‐year trial of oral naproxen sodium 220 mg b.i.d. for mitigation of presymptomatic AD biomarker progression,[6](#acn3788-bib-0006){ref-type="ref"} we therefore explored CNS permeability of naproxen and the corresponding change in immune markers.

Methods {#acn3788-sec-0002}
=======

Participants {#acn3788-sec-0003}
------------

INTREPAD, a recently completed 2‐year placebo‐controlled trial of naproxen 220 mg b.i.d. for AD prevention,[6](#acn3788-bib-0006){ref-type="ref"} enrolled 101 cognitively unimpaired (CU) serial CSF donors with a parental or multiple‐sibling history of "sporadic" AD.[7](#acn3788-bib-0007){ref-type="ref"} These were 55 or more years of age (most aged 60+). Two or more lumbar punctures were available from 78, the first at baseline in all but two instances (Table [1](#acn3788-tbl-0001){ref-type="table"}). Each participant and study partner provided written informed consent. All procedures were approved by the McGill University Faculty of Medicine Institutional Review Board. All research complied with ethical principles of the Declaration of Helsinki.

###### 

Sample characteristics

                            Baseline                                   3 Months          12 Months          24 Months                                                                                                                                                                                                
  ------------------------- ------------------------------------------ ----------------- ------------------ ----------- ------------------ ------------------ ------------------ ---------- ------------------ ------------------ ------------------ ------ ------------------ ------------------ ------------------ ------
  *N*                       76[1](#acn3788-note-0001){ref-type="fn"}   33                43                             73                 29                 44                            72                 32                 30                        66                 30                 36                 
  Age (years)               62.70 (5.53)                               61.90 (5.35)      63.31 (5.66)       0.27        63.01 (5.35)       61.84 (4.59)       63.80 (5.71)       0.11       63.62 (4.85)       62.88 (5.13)       64.21 (4.59)       0.26   63.86 (4.54)       62.96 (4.36)       64.61 (4.61)       0.14
  Sex (M:F)                 24:52                                      9:24              15:28              0.62        22:51              7:22               15:29              0.44       22:50              7:25               15:25              0.20   19:47              6:24               13:23              0.18
  %APOE                     38.2                                       42.4              34.9               0.63        38.4               30.2               34.1               0.46       37.5               43.8               32.5               0.34   37.9               43.3               33.3               0.45
  CSF A*β* ~1‐42~ (pg/mL)   1136.04 (286.80)                           1160 (239.67)     1117.28 (319.83)   0.50        1124.69 (296.92)   1146.78 (283.63)   1110.13 (307.71)   0.60       1125.54 (298.57)   1131.67 (281.43)   1120.64 (315.08)   0.88   1109.03 (298.15)   1173.33 (279.99)   1055.44 (305.99)   0.11
  CSF t‐*tau* (pg/mL)       274.56 (131.01)                            258.32 (118.94)   287.03 (139.65)    0.33        282.60 (141.31)    240.38 (79.79)     310.43 (165.22)    **0.02**   283.84 (132.39)    257.19 (120.92)    305.16 (138.70)    0.12   295.48 (170.78)    286.72 (177.33)    302.78 (167.30)    0.71
  CSF P‐*tau* (pg/mL)       47.68 (18.23)                              45.57 (16.81)     49.30 (19.29)      0.37        47.19 (17.40)      43.53 (13.73)      49.61 (19.22)      0.12       47.57 (17.15)      45.20 (16.97)      49.47 (17.27)      0.30   46.72 (18.79)      45.46 (17.20)      47.76 (20.21)      0.62

Two participants did not receive a lumbar puncture until the 3‐months visit.
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CSF measurements {#acn3788-sec-0004}
----------------

CSF collection and storage as well as *APOE* genotyping were performed as described.[8](#acn3788-bib-0008){ref-type="ref"} We measured concentrations of the "classic" AD biomarkers A*β* ~1‐42~, total‐*tau* (t‐*tau*), and P~181~‐*tau* (P‐*tau*) using the INNOTEST ELISA kit (Fujirebio, Ghent, Belgium). CSF apolipoprotein E (apoE) levels were assessed using the Milliplex APOMAG‐62k multiplex kit, and 29 immune proteins were assayed using the Milliplex HCYTMAG60PMX29BK xMap kit (EMD Millipore, Billerica, MA). We excluded marker analyses with coefficient of variation \>15% or missing data \>20%, leaving 13 protein species for analysis. We also used mass spectrometry to assay naproxen concentrations in plasma and CSF of 57 and 30 participants, respectively, using methods described elsewhere.[9](#acn3788-bib-0009){ref-type="ref"} Data collected at the trial\'s 3‐ and 12‐month evaluations were discarded for two participants who had previously discontinued treatment.

Statistical analyses {#acn3788-sec-0005}
--------------------

Group comparisons of summary statistics used *t*‐tests and Fisher\'s exact test when appropriate. Mann--Whitney *U*‐tests compared baseline levels of CSF protein markers along with plasma and CSF naproxen concentrations.

### Naproxen and CSF immune markers {#acn3788-sec-0006}

We tested data for normality, applied Box‐Cox transformation when necessary, and calculated *Z*‐scores. Paired *t*‐tests and linear models adjusted for age and sex, as appropriate, compared within‐ and between‐treatment group marker levels at each time point. We then tested for association of naproxen concentration and protein marker levels. Mass spectrometry assays for CSF naproxen concentration were obtained for 30 (18 naproxen‐assigned and 12 placebo‐assigned) participants. We then performed a linear mixed‐effects analysis to test whether CSF immune marker levels changed over the trial period, adjusting for age, sex, *APOE ε*4 carrier status, and compliance as well as CSF t‐*tau* and A*β* ~1‐42~ concentrations. When there was a statistically significant change over time, we repeated the linear mixed‐effects analysis, now adding an interaction term for treatment‐by‐time to test for a difference in slope of change between treatment groups. Naproxen‐treated participants had concurrent measurement of CSF markers and naproxen at 3, 12, and 24 months of follow‐up (16, 16, and 4 participants). We used general linear regression models, adjusted for *APOE* carrier status and age, to investigate the association of naproxen concentrations with 3‐ and 12‐month protein marker levels. We repeated this analysis pooling all available postbaseline data while also considering participant sex, and CSF t‐*tau* and A*β* ~1‐42~, because immune marker levels are associated with AD biomarkers.[8](#acn3788-bib-0008){ref-type="ref"} All analyses used two‐sided *α* = 0.05 in MATLAB software (MathWorks Inc., Natick, Massachusetts).

Results {#acn3788-sec-0008}
=======

Summary statistics {#acn3788-sec-0009}
------------------

Among the 78 participants analyzed, 4 (1 placebo and 3 naproxen), 8 (3 placebo and 5 naproxen), and 66 (30 placebo and 36 naproxen) participants completed 3‐, 12‐, and 24‐month visits on treatment. At baseline, naproxen‐ and placebo‐assigned groups were indistinguishable in sex ratios, proportion of *APOE ε*4 allele carriage, or CSF P‐*tau*, t‐*tau*, and A*β* ~1‐42~ levels. The naproxen‐assigned group was somewhat older (*P* = 0.27). Baseline immune marker concentrations were comparable between groups except for IL‐6 levels, which trended higher in participants assigned to naproxen (*P* = 0.08).

Naproxen enters the brain of treated individuals {#acn3788-sec-0010}
------------------------------------------------

No participants had measurable naproxen levels in either plasma or CSF at baseline (before randomization). At follow‐up, only naproxen‐assigned participants had measurable drug in either plasma or CSF (Fig. [1](#acn3788-fig-0001){ref-type="fig"}). Follow‐up assays revealed two naproxen‐assigned individuals who had measurable drug in plasma but not in CSF. Otherwise, CSF concentrations were typically \~100‐fold lower than in plasma. Pooling all available postbaseline data revealed little if any association between CSF and plasma concentrations of naproxen (*R* ^2^ = 0.02, *P* = 0.37) and a marginal association of CSF naproxen with age (*R* ^2^ = 0.08, *P* = 0.08). Variability in apparent CNS permeability to naproxen (i.e., CSF naproxen concentration) was not appreciably associated with compliance.

![Plasma and CSF concentrations of naproxen in the trial cohort. Plasma (left) and CSF (right) concentrations of naproxen were measured in placebo (yellow)‐ and naproxen (blue)‐assigned participants using LC--MS/MS. The placebo group showed no measurable levels of the drug at any time point. Naproxen‐assigned participants had readily detectable naproxen in plasma, but \~100‐fold lower concentrations in CSF at each follow‐up (note the difference in *y*‐axis scales). Red lines depict medians, bold lines represent the 25th and 75th percentile, and thin black lines represent the minimum and maximum values not considered to be outliers (first and third quartile ± 1.5 times the interquartile range).](ACN3-6-1127-g001){#acn3788-fig-0001}

Naproxen does not affect concentrations of CSF immune markers {#acn3788-sec-0011}
-------------------------------------------------------------

IL‐1RA, IFN‐*α*2, and apoE levels increased from baseline over the trial period in both treatment groups (Fig. [2](#acn3788-fig-0002){ref-type="fig"}). However, these changes were comparable across the treatment groups at all time points, suggesting that they might uniformly reflect aging of the population[10](#acn3788-bib-0010){ref-type="ref"}, [11](#acn3788-bib-0011){ref-type="ref"} and not an effect of naproxen. IL‐6 levels declined significantly at 3, 12, and 24 months in naproxen‐assigned participants only, but fell readily within the distribution of placebo participants. A linear mixed‐effects analysis indicated that apoE concentration increased substantially over the trial interval, independent of age, sex, *APOE ε4* carrier status, compliance, and CSF t‐*tau* or A*β* ~1‐42~ (*β* = 0.13 units/month, SE = 0.06, *P* = 0.03). This 2‐year slope of apoE concentrations appeared steeper in naproxen‐assigned participants versus placebo (time‐by‐treatment interaction *β* = +0.02 units/month, SE = 0.01, *P* = 0.09). Interestingly, 3‐ and 12‐month CSF naproxen concentrations appeared to be associated with CSF apoE protein (*β* = 4.10, SE = 2.28, *P* = 0.10 and *β* = 3.13, SE = 1.24, *P* = 0.03), with adjustment for *APOE ε4* carrier status and age. Upon pooling all postbaseline data in the naproxen‐assigned group, the association between drug and apoE concentration was stronger and apparently independent of age, sex, *APOE ε4* carrier status, and CSF t‐*tau* and A*β* ~1‐42~ (*β* = 3.10, SE = 0.86, *P* = 0.001). Interpretation of this last observation is difficult, however, because no detectable difference appeared in mean apoE concentrations at all time points across the two treatment arms. This finding may relate to a relative (not statistically significant) difference in baseline apoE levels between the two groups. Further adjustment for this variable indicated a difference in slope between the treatment groups (time‐by‐treatment interaction *β* = +0.02 units/month, SE = 0.01, *P* = 0.04). All results remained similar when restricting our analyses to the 66 participants who completed 24 months on study drug.

![Trajectory of CSF immune markers by treatment group. Longitudinal CSF levels of immune markers in the placebo (yellow) and naproxen (blue) groups are represented. Point estimates represent group means and error bars standard error of the mean. IL‐6 levels tended to be higher at baseline in the naproxen‐assigned group compared to placebo (*P* ≤ 0.1). IL‐1RA,IFN‐*α*2, and apoE levels increased from baseline in both treatment groups over the trial period. IL‐6 levels decreased significantly at 3, 12, and 24 months compared to baseline in naproxen‐assigned participants only. At all postbaseline time points, immune marker levels were comparable between both treatment arms. ^+^ *P*  \< 0.1; ^\*^ *P* \< 0.05; ^\*\*^ *P* \< 0.01; ^\*\*\*^ *P* \< 0.005.](ACN3-6-1127-g002){#acn3788-fig-0002}

Discussion {#acn3788-sec-0012}
==========

In a sample of healthy elderly at increased risk for AD dementia, we examined whether 220 mg of oral naproxen b.i.d. entered the CSF and thereby affected immune marker concentrations. While drug levels were measurable in plasma, CSF concentrations were \~100‐fold lower. Naproxen treatment did not meaningfully alter CSF concentrations of several immune markers. CSF apolipoprotein E concentrations increased during the trial period, and the results suggested its association with CSF naproxen concentrations.

Early epidemiologic observations of reduced AD risk with NSAID treatment led to widespread speculation that these drugs produced a beneficial suppression of inflammatory responses to accruing pathology. However, this interpretation has never been verified. While the inhibition of cyclooxygenase activity (the proximate target of NSAID activity) can lead to reduced inflammation, NSAIDs also have other effects. For instance, some NSAIDs may reduce accrual of A*β* pathology itself,[12](#acn3788-bib-0012){ref-type="ref"} while others may promote neuronal survival.[13](#acn3788-bib-0013){ref-type="ref"} However, few human studies have examined whether NSAIDs cross the blood--brain barrier. Our results suggest CSF permeability for naproxen is limited, much like other conventional NSAIDs.[14](#acn3788-bib-0014){ref-type="ref"} While it is uncertain whether CSF levels of naproxen fully reflect brain levels, the proportion of drug in CSF compared to blood is comparable to what is measurable in brain tissue in animal models.[15](#acn3788-bib-0015){ref-type="ref"}, [16](#acn3788-bib-0016){ref-type="ref"} Thus, brain levels of naproxen may never reach levels needed to observe the neuroprotective effects described in vitro.[17](#acn3788-bib-0017){ref-type="ref"} Drug levels were, nonetheless, sufficiently measurable in CSF to suggest no meaningful effects on immune marker activity. One important limitation is that some immune markers may be actively transported across the BBB and possibly hide the apparent effects of naproxen on immune markers. However, while IL‐6 may be actively transported across the BBB,[18](#acn3788-bib-0018){ref-type="ref"} our IL‐6 results appear to suggest nothing more than regression toward the mean among treated individuals. More importantly, the contribution of contamination -- if any -- to CSF concentration of immune markers is unknown, and one would expect that a decrease in global brain immune reactivity would be reflected at the CSF level, as it is for amyloid and *tau*. By contrast, CSF naproxen concentrations *were* associated with increasing CSF apoE levels. One of us (J.P.) had previously shown that NSAIDs may increase astrocytic production of apoE[19](#acn3788-bib-0019){ref-type="ref"} and that this apparent effect was obtained at NSAID concentrations below those typically required for COX inhibition.

We conclude that it is unlikely that a central "anti‐inflammatory" effect would be responsible for any purported benefit of NSAIDs, if any, in protecting against the development of AD. Our findings suggest instead that NSAID benefits may stem from increased apoE concentration in proportion to drug levels. However, this drug‐related increase was not strong enough to obviate increasing apoE levels over time, possibly as a consequence of aging. Before being regarded as conclusive, these results require replication, possibly in a larger group of individuals. We cannot, however, exclude that NSAIDs still bear some influence on CNS immune pathways not measured here or that peripheral immune system activation might in some way modulate risk of AD pathology.[20](#acn3788-bib-0020){ref-type="ref"}
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